Biogen: Jefferies maintains its rating on the title

(CercleFinance.com) – Jefferies maintains its Buy recommendation on Biogen stock and its price target at $240. “The FDA briefing materials for Friday’s AdCom of Leqembi are relatively positive,” begins the analyst who anticipates an upvote regarding his clinical benefit. “We expect straight-forward approval and no major labeling issues,” the broker says. The launch will take…

Read More

Walmart: Jefferies maintains opinion

(CercleFinance.com) – Jefferies maintains its Buy recommendation and its price target of $175 on Walmart stock. “We are encouraged by Walmart’s recent automation deployments and its expansion plans for the future,” the analyst said. “Walmart expects these new processes to reduce average unit economic costs by nearly 20% by the end of 2026,” the broker…

Read More